Couverture de Podcast with MedAsian

Podcast with MedAsian

Podcast with MedAsian

De : Rex
Écouter gratuitement

À propos de ce contenu audio

China healthcare policy landscape

© 2026 Podcast with MedAsian Art
Épisodes
  • Innovation Is Easy, Governance Is Hard: AI’s Next Challenge in Healthcare (Part I)

    Innovation Is Easy, Governance Is Hard: AI’s Next Challenge in Healthcare (Part I)
    Apr 27 2026
    • Surge drivers: Advances in deep learning and large language models, mounting pressure from aging populations and rising costs, plus heavy investment and government backing are converging to make AI a practical, system-shaping force in healthcare.


    • Market size: The global AI healthcare market could approach $190 billion by 2030, with China’s medical large-model segment alone surpassing RMB 100 billion, touching the full value chain from drug discovery to post-care.


    • Evolution & applications: AI has moved from rigid expert systems to narrow deep-learning tools to today’s multimodal models that reason across imaging, records, and genomics. It now spans clinical decision support, drug R&D, public health, and hospital operations.


    • Key risks: Data privacy, biased outcomes from unrepresentative training data, “black box” opacity, and unclear accountability when AI is involved in clinical decisions.


    • Governance as the real bottleneck: Technology is advancing faster than regulation. Without clear rules on responsibility, safety, and transparency, even the most advanced AI cannot win trust or achieve sustainable adoption.


    • Regional governance models: The US relies on adaptive, market-driven frameworks (e.g., FDA) but faces fragmentation; the EU enforces strict, rights-based rules via the AI Act, prioritizing safety; China takes a state-led, rapid-scaling approach with evolving regulatory oversight.


    • Core message: For AI to responsibly transform healthcare, governance must catch up with innovation—ensuring ethics, accountability, and trust are built into the system from the start.
    Afficher plus Afficher moins
    21 min
  • From Steel to Stem Cells: How a 1962 Cold War Trade Law Is Quietly Redrawing the Global Pharma Map (Part 2)

    From Steel to Stem Cells: How a 1962 Cold War Trade Law Is Quietly Redrawing the Global Pharma Map (Part 2)
    Apr 15 2026
    • For multinational pharma in China: A strategic trade-off emerges between US market access and global efficiency. High tariffs penalize offshore production, pushing firms from “China for Global” to “China for China” models. Expect more US-based manufacturing, fragmented supply chains, and pricing pressures (e.g., MFN agreements).
    • For Chinese pharma companies: Diversify exports beyond the US (Europe, SE Asia, Middle East). Move up the value chain into novel drugs and integrated services. Boost compliance, traceability, and governance to meet rising global scrutiny. Elevate government affairs as a core capability.
    • Domestic reshaping of China’s pharma industry: External pressure will accelerate innovation, strengthen domestic demand, and push industrial upgrading toward high-end manufacturing and self-reliance.
    • Broader US-China dynamics: Healthcare becomes a new front in strategic competition. Supply chains are now national security assets; trade and regulation are tools to reshape global industrial structures.
    • Global business takeaway: Efficiency is no longer king. Security, resilience, and policy alignment now drive supply chains and market access. Government affairs is a strategic necessity in politically shaped markets.
    Afficher plus Afficher moins
    17 min
  • From Steel to Stem Cells: How a 1962 Cold War Trade Law Is Quietly Redrawing the Global Pharma Map

    From Steel to Stem Cells: How a 1962 Cold War Trade Law Is Quietly Redrawing the Global Pharma Map
    Apr 9 2026
    1. What is Section 232? A U.S. trade law allowing the President to restrict imports deemed a threat to "national security." It is now being applied to pharmaceuticals, reframing medicine as a strategic asset rather than just a commercial good.
    2. Why Now? The shift is driven by three converging factors: supply chain vulnerability exposed by recent crises, intensifying geopolitical competition extending into healthcare, and a domestic desire to use trade leverage to lower U.S. drug prices.
    3. How It Works: The policy is a three-step system: High Tariffs (up to 100%) penalize offshore production, Onshoring Incentives offer temporary relief for relocating manufacturing to the U.S., and MFN Pricing Agreements grant zero-tariff access in exchange for lower U.S. prices.
    4. Impact on U.S. Industry: Long-term, this forces a re-localization of manufacturing and shifts the industry from a market-driven model to a policy-dependent ecosystem where government affairs become a core business function.
    5. Immediate Impact on Chinese Firms: Short-term effects are buffered by exemptions for generics and APIs. However, long-term pressure is building on CDMOs and high-end manufacturing as global supply chains begin to re-segment and decouple.
    Afficher plus Afficher moins
    25 min
Aucun commentaire pour le moment